FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229334802> ?p ?o ?g. }

• W4229334802 endingPage "4133" @default.
• W4229334802 startingPage "4122" @default.
• W4229334802 abstract "Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non-small-cell lung cancer (NSCLC) patients is under active clinical investigation. Thus, it would be necessary and meaningful to study the molecular and clinical characteristics of IDH mutation in NSCLC patients, especially in the Chinese population.A total of 17,978 Chinese patients with NSCLC who underwent next -generation sequencing (NGS) testing were retrospectively reviewed.We identified 161 unique IDH mutations in 361 of 17,978 patients (2.01%). Common active-site mutations, including IDH1R100 , IDH1R132 , IDH2R140 , and IDH2R172 , were detected in 154 patients (0.86%) and were associated with male sex (p = 0.004) and older age (p = 0.02). The IDH mutation spectra observed in NSCLC were quite different from those in glioma or AML. Patients with IDH active-site mutations exhibited significantly higher coalterations in KRAS (p. G12/13/61, 22.1% vs. 8.2%, p < 0.001) or BRAF (p. V600E, 6.5% vs. 1.0%, p < 0.001), but significantly lower coalterations in activating EGFR (e18-e20, 22.7 vs. 37.9%, p < 0.001) than IDH wild-type patients. Furthermore, we found that active-site IDH mutations were correlated with a short PFS (2-5.6 months) and short OS (2-9.5 months), which may arise as a resistance mechanism against common targeted drugs. In vitro, we experimentally observed that the combination of an IDH inhibitor and EGFR TKI could better inhibit lung cancer cell proliferation than an EGFR TKI alone.Taken together, this study reveals the molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and provides a theoretical basis for IDH-directed treatment. The potential of IDH mutations as response markers for targeted therapy warrants further investigation." @default.
• W4229334802 created "2022-05-09" @default.
• W4229334802 creator A5003459470 @default.
• W4229334802 creator A5005228021 @default.
• W4229334802 creator A5017708293 @default.
• W4229334802 creator A5021315826 @default.
• W4229334802 creator A5028411768 @default.
• W4229334802 creator A5031804038 @default.
• W4229334802 creator A5032857124 @default.
• W4229334802 creator A5035762469 @default.
• W4229334802 creator A5036612761 @default.
• W4229334802 creator A5036665967 @default.
• W4229334802 creator A5036905517 @default.
• W4229334802 creator A5047730128 @default.
• W4229334802 creator A5056918247 @default.
• W4229334802 creator A5061817335 @default.
• W4229334802 creator A5066638147 @default.
• W4229334802 creator A5073021091 @default.
• W4229334802 creator A5084203482 @default.
• W4229334802 creator A5090263356 @default.
• W4229334802 date "2022-05-08" @default.
• W4229334802 modified "2023-10-18" @default.
• W4229334802 title "Molecular and clinical characteristics of <scp>IDH</scp> mutations in Chinese <scp>NSCLC</scp> patients and potential treatment strategies" @default.
• W4229334802 cites W1834978976 @default.
• W4229334802 cites W1973096044 @default.
• W4229334802 cites W1989188414 @default.
• W4229334802 cites W1995675594 @default.
• W4229334802 cites W2020665022 @default.
• W4229334802 cites W2040827479 @default.
• W4229334802 cites W2044433401 @default.
• W4229334802 cites W2064310798 @default.
• W4229334802 cites W2074448607 @default.
• W4229334802 cites W2080452140 @default.
• W4229334802 cites W2085335768 @default.
• W4229334802 cites W2096796171 @default.
• W4229334802 cites W2111163869 @default.
• W4229334802 cites W2126817554 @default.
• W4229334802 cites W2134061682 @default.
• W4229334802 cites W2134151441 @default.
• W4229334802 cites W2138601221 @default.
• W4229334802 cites W2142850084 @default.
• W4229334802 cites W2146290346 @default.
• W4229334802 cites W2147734470 @default.
• W4229334802 cites W2150575159 @default.
• W4229334802 cites W2154313451 @default.
• W4229334802 cites W2168784615 @default.
• W4229334802 cites W2265127337 @default.
• W4229334802 cites W2582446241 @default.
• W4229334802 cites W2588385654 @default.
• W4229334802 cites W2609243345 @default.
• W4229334802 cites W2753207486 @default.
• W4229334802 cites W2802354838 @default.
• W4229334802 cites W2803357178 @default.
• W4229334802 cites W2806682325 @default.
• W4229334802 cites W2806946493 @default.
• W4229334802 cites W2867868648 @default.
• W4229334802 cites W2896480326 @default.
• W4229334802 cites W2897720285 @default.
• W4229334802 cites W2911333477 @default.
• W4229334802 cites W2913322626 @default.
• W4229334802 cites W2942027709 @default.
• W4229334802 cites W2946179114 @default.
• W4229334802 cites W2959525851 @default.
• W4229334802 cites W2981927287 @default.
• W4229334802 cites W3018464109 @default.
• W4229334802 cites W3083073139 @default.
• W4229334802 cites W3093100939 @default.
• W4229334802 cites W3168617320 @default.
• W4229334802 cites W4229334802 @default.
• W4229334802 doi "https://doi.org/10.1002/cam4.4764" @default.
• W4229334802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35526267" @default.
• W4229334802 hasPublicationYear "2022" @default.
• W4229334802 type Work @default.
• W4229334802 citedByCount "1" @default.
• W4229334802 countsByYear W42293348022022 @default.
• W4229334802 crossrefType "journal-article" @default.
• W4229334802 hasAuthorship W4229334802A5003459470 @default.
• W4229334802 hasAuthorship W4229334802A5005228021 @default.
• W4229334802 hasAuthorship W4229334802A5017708293 @default.
• W4229334802 hasAuthorship W4229334802A5021315826 @default.
• W4229334802 hasAuthorship W4229334802A5028411768 @default.
• W4229334802 hasAuthorship W4229334802A5031804038 @default.
• W4229334802 hasAuthorship W4229334802A5032857124 @default.
• W4229334802 hasAuthorship W4229334802A5035762469 @default.
• W4229334802 hasAuthorship W4229334802A5036612761 @default.
• W4229334802 hasAuthorship W4229334802A5036665967 @default.
• W4229334802 hasAuthorship W4229334802A5036905517 @default.
• W4229334802 hasAuthorship W4229334802A5047730128 @default.
• W4229334802 hasAuthorship W4229334802A5056918247 @default.
• W4229334802 hasAuthorship W4229334802A5061817335 @default.
• W4229334802 hasAuthorship W4229334802A5066638147 @default.
• W4229334802 hasAuthorship W4229334802A5073021091 @default.
• W4229334802 hasAuthorship W4229334802A5084203482 @default.
• W4229334802 hasAuthorship W4229334802A5090263356 @default.
• W4229334802 hasBestOaLocation W42293348021 @default.
• W4229334802 hasConcept C104317684 @default.
• W4229334802 hasConcept C121608353 @default.
• W4229334802 hasConcept C126322002 @default.

• next